2025-11-26 マウントサイナイ医療システム(MSHS)
Peptibody-mediated bacterial killing and immune activation mechanisms. Image Credit: Created in BioRender. Hou, X., Icahn School of Medicine at Mount Sinai.
<関連情報>
- https://www.mountsinai.org/about/newsroom/2025/experimental-mrna-therapy-shows-potential-to-combat-antibiotic-resistant-infections
- https://www.nature.com/articles/s41587-025-02928-x
抗炎症脂質中のペプチボディmRNAとして抗菌ペプチドを肺に送達することで、多剤耐性細菌性肺炎を治療する Antimicrobial peptide delivery to lung as peptibody mRNA in anti-inflammatory lipids treats multidrug-resistant bacterial pneumonia
Yonger Xue,Xucheng Hou,Siyu Wang,Yuebao Zhang,Yichen Zhong,Diana D. Kang,Chang Wang,Haoyuan Li,Changyue Yu,Zhengwei Liu,Meng Tian,Dinglingge Cao,Ya Ying Zheng,Binbin Deng,Pauline Hamon,Miriam Merad & Yizhou Dong
Nature Biotechnology Published:26 November 2025
DOI:https://doi.org/10.1038/s41587-025-02928-x
Abstract
The efficacy of antimicrobial peptides (AMPs) is limited by challenges of delivery and potency. We enhance AMP performance in the lung by converting AMPs to a peptibody format that fuses AMPs with fragment crystallizable domains to activate innate immunity and cathelin domains for infection-responsive activation, with their mRNA constructs delivered by anti-inflammatory lipid nanoparticles. The highest-scoring design outperforms antibiotic therapy approved by the US Food and Drug Administration in multidrug-resistant pneumonia models, eradicating representative MDR bacteria while mitigating inflammation.
